Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

3,039 2,500 Total current liabilities 4,578 4,480 Capital lease obligation - non-current 49 7 Equipment loan - non-current 497 470 Deferred revenue - non-current 4,478 1,667 Total liabilities 9,602 6,624 Stockholders' Equity: Common stock, $0.01 par value; 65,000 and 65,000 shares authorized at December 31, 2007 and December 31, 2008, respectively, 21,269 and 21,471 shares issued and outstanding at December 31, 2007 and December 31, 2008, respectively. 212 215 Additional paid-in capital 32,585 33,718 Accumulated other comprehensive income (loss) (3) - Accumulated deficit during development stage (18,474) (26,588) Total stockholders' equity 14,320 7,345 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,922 $13,969 CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Cumulative Period from July 1, 2002 (date of development stage inception) to Year Ended December 31, December 31, 2006 2007 2008 2008 REVENUE License and collaboration revenue $1,533 $5,913 $6,722 $14,168 Total revenue
'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... develops and commercializes proprietary technologies and products for advanced ... for the fiscal first quarter ended December  31, 2014. ... dollars (CAD), unless otherwise stated. "During ... from our existing customers and add to our sales ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... Burbano to senior associate and project architects Tess Kavanagh and ... firm ( http://www.ratcliffarch.com ) provides a ... healthcare, academic and civic clients throughout the Western United States. ... 20 years of architectural design experience. He is currently ...
... , , SAN DIEGO, June 4 Neurocrine ... Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences ... Conference in New York. , , The live ... Eastern Time (ET)/10:30 a.m. Pacific Time (PT). The presentation ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... of ANA598, in particular a proposed Phase II study in ... and ribavirin. , , As part of ... ANA773 and is reducing its workforce by approximately 40%. ...
Cached Biology Technology:Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate 2Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 3Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 4Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 5
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)...  Analyst Report Issued by Small Cap IR. In 2011, Nilson ... transactions at merchants on the leading payment cards rose to ... debit, and prepaid cards reached 6.54 billion.  Eight million credit ... usage in 2012, and credit and debit card fraud resulted ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... zoonotic pathogens from previously unrecognized wildlife reservoirs remains one ... past century, numerous pathogens have emerged and re-emerged with ... 18 months, and the majority have zoonotic origins in ... Nile Virus. The National Institute for Mathematical ...
... This release is available in French . ... Technology Prize was given today, June 9, to EPFL professor ... for the extraordinary career of the man whose dye-sensitized solar ... for Michael Grtzelafter consecrating thirty years to the development of ...
... but gasoline, computers, and tennis shoes just might thanks ... produce fuel, plastics, and other chemicals from plants instead ... the current issue of Chemical & Engineering News (C&EN), ... Melody Voith notes that today,s plant-based fuels and plastics ...
Cached Biology News:
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
... The ChIP (Chemical Inkjet Printer) ... Peptide Mass Fingerprinting and Protein Macroarray ... proteomics company, ProteomeSystems. The strategy compliments ... 2-D gels (using the proteins isoelectric ...
...
... to the third cytoplasmic loop of human ... KLH. The immunizing peptide has 79% homology ... Physical form: Solution in phosphate buffered saline, ... Titertest method: IHC (p). Titertest values: ...
Biology Products: